Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 25, Issue 12, 2005, Pages 2615-2622

  Ikewaki, Katsunori ^a   Schaefer, Juergen R ^b   Frischmann, Michael E ^c   Okubo, Keio ^a   Hosoya, Tatsuo ^a   Mochizuki, Seibu ^a   Dieplinger, Benjamin ^d   Trenkwalder, Evi ^c   Schweer, Horst ^b   Kronenberg, Florian ^c,e   Koenig, Paul ^c   Dieplinger, Hans ^c  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Cardiovascular diseases; Isotopes; Kidney; Lipoproteins; Metabolism

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LEUCINE; LOW DENSITY LIPOPROTEIN; DEUTERIUM; DIAGNOSTIC AGENT; LIPOPROTEIN; LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ETHNIC GROUP; GAS CHROMATOGRAPHY; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; LIPOPROTEIN METABOLISM; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; BLOOD; CHRONIC KIDNEY FAILURE; KINETICS; METABOLISM; MIDDLE AGED; PREVALENCE; RENAL REPLACEMENT THERAPY; RISK FACTOR;

ADULT; APOLIPOPROTEINS B; ATHEROSCLEROSIS; CHOLESTEROL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; DEUTERIUM; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HUMANS; KIDNEY FAILURE, CHRONIC; KINETICS; LIPOPROTEINS; MALE; MIDDLE AGED; PREVALENCE; RENAL DIALYSIS; RISK FACTORS;

EID: 30744476783     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000188555.60475.c2     Document Type: Article

References (54)

1. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974;290:697-701.
2. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32:S112-S119.
3. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet. 2000;356:147-152.
4. Kronenberg F. Homocysteine, lipoprotein(a) and fibrinogen: metabolic risk factors for cardiovascular complications of chronic renal disease. Curr Opin Nephrol Hypertens. 1998;7:271-278.
5. Kronenberg F. Lipoprotein abnormalities in end-stage renal failure. In: Loscalzo J, London GM, eds. Cardiovascular disease in end-stage renal failure. Oxford, UK: Oxford University Press; 2000:175-206.
6. Bagdade JD, Porte D Jr, Bierman EL. Hypertriglyceridemia. A metabolic consequence of chronic renal failure. N Engl J Med. 1968;279:181-185.
7. Chan MK, Varghese Z, Moorhead JF. Lipid abnormalities in uremia, dialysis, and transplantation. Kidney Int. 1981;19:625-637.
8. Shoji T, Ishimura E, Inaba M, Tabata T, Nishizawa Y. Atherogenic lipoproteins in end-stage renal disease. Am J Kidney Dis. 2001;38:S30-S33.
9. Kronenberg F, Utermann G, Dieplinger H. Lipoprotein(a) in renal disease. Am J Kidney Dis. 1996;27:1-25.
10. Fuh MMT, Lee C-M, Jeng C-Y, Shen D-C, Shieh S-M, Reaven GM, Chen Y-DI. Effect of chronic renal failure on high-density lipoprotein kinetics. Kidney Int. 1990;37:1295-1300.
11. Dieplinger H, Schoenfeld PY, Fielding CJ. Plasma cholesterol metabolism in end-stage renal disease. Difference between treatment by hemodialysis or peritoneal dialysis. J Clin Invest. 1986;77:1071-1083.
12. Kronenberg F, König P, Neyer U, Auinger M, Pribasnig A, Lang U, Reitinger J, Pinter G, Utermann G, Dieplinger H. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continous ambulatory peritoneal dialysis. J Am Soc Nephrol. 1995;6:110-120.
13. O'Neal D, Lee P, Murphy B, Best J. Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis. Am J Kidney Dis. 1996;27:84-91.
14. Sacks FM, Campos H. Clinical review 163: Cardiovascular endocrinology: low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocrinol Metab. 2003;88:4525-4532.
15. Chan MK, Persaud J, Varghese Z, Moorhead JF. Pathogenic roles of post-heparin lipases in lipid abnormalities in hemodialysis patients. Kidney Int. 1984;25:812-818.
16. Chan PC, Persaud J, Varghese Z, Kingstone D, Baillod RA, Moorhead JF. Apolipoprotein B turnover in dialysis patients: its relationship to pathogenesis of hyperlipidemia. Clin Nephrol. 1989;31:88-95.
17. Hörkkö S, Huttunen K, Kesäniemi YA. Decreased clearance of low-density lipoprotein in uremic patients under dialysis treatment. Kidney Int. 1995:47:1732-1740.
18. Hörkkö S, Huttunen K, Korhonen T, Kesäniemi YA. Decreased clearance of low-density lipoprotein in patients with chronic renal failure. Kidney Int. 1994;45:561-570.
19. Prinsen BH, Rabelink TJ, Romijn JA, Bisschop PH, de Barse MM, de Boer J, van Haeften TW, Barrett PH, Berger R, de Sain-van der Velden MG. A broad-based metabolic approach to study VLDL apoB100 metabolism in patients with ESRD and patients treated with peritoneal dialysis. Kidney Int. 2004;65:1064-1075.
20. Schaefer JR, Rader DJ, Brewer BHJ. Investigation of lipoprotein kinetics using endogenous labeling with stable isotopes. Curr Opin Lipidol. 1992;3:227-232.
21. Schaefer JR, Scharnagl H, Baumstark MW, Schweer H, Zech LA, Seyberth H, Winkler K, Steinmetz A, Marz W. Homozygous familial defective apolipoprotein B-100. Enhanced removal of apolipoprotein E-containing VLDLs and decreased production of LDLs. Arterioscler Thromb Vasc Biol. 1997;17:348-353.
22. Ikewaki K, Rader DJ, Schaefer JR, Fairwell T, Zech LA, Brewer HB Jr. Evaluation of apoA-I kinetics in humans using simultaneous endogenous stable isotope and exogenous radiotracer methods. J Lipid Res. 1993;34:2207-2215.
23. Schweer H, Watzer B, Seyberth HW, Steinmetz A, Schaefer JR. Determination of isotopic ratios of L-leucine and L-phenylalanine and their stable isotope labeled analogues in biological samples by gas chromatography/triple-stage quadrupole mass spectrometry. J Mass Spectrom. 1996;31:727-734.
24. Cobelli C, Toffolo G, Foster DM. Tracer-to-tracee ratio for analysis of stable isotope tracer data: link with radioactive kinetic formalism. Am J Physiol. 1992;262:E968-E975.
25. Barrett PH, Bell BM, Cobelli C, Golde H, Schumitzky A, Vicini P, Foster DM. SAAM II: simulation, analysis, and modeling software for tracer and pharmacokinetic studies. Metabolism. 1998;47:484-492.
26. Ikewaki K, Nishiwaki M, Sakamoto T, Ishikawa T, Fairwell T, Zech LA, Nagano M, Nakamura H, Brewer HB Jr, Rader DJ. Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency. J Clin Invest. 1995;96:1573-1581.
27. Kronenberg F, Trenkwalder E, Kronenberg MF, König P, Utermann G, Dieplinger H. Influence of hematocrit on the measurement of lipoproteins demonstrated by the example of lipoprotein(a). Kidney Int. 1998;54:1385-1389.
28. Kaysen GA, Dubin JA, Muller HG, Mitch WE, Rosales L, Levin NW. Impact of albumin synthesis rate and the acute phase response in the dual regulation of fibrinogen levels in hemodialysis patients. Kidney Int. 2003;63:315-322.
29. Giordano M, De Feo P, Lucidi P, dePascale E, Giordano G, Infantone L, Zoccolo AM, Castellino P. Increased albumin and fibrinogen synthesis in hemodialysis patients with normal nutritional status. J Am Soc Nephrol. 2001;12:349-354.
30. Mitra S, Chamney P, Greenwood R, Farrington K. Serial determinations of absolute plasma volume with indocyanine green during hemodialysis. J Am Soc Nephrol. 2003;14:2345-2351.
31. Weidmann P, Beretta-Piccoli C, Steffen F, Blumberg A, Reubi FC. Hypertension in terminal renal failure. Kidney Int. 1976;9:294-301.
32. Katzarski KS, Nisell J, Randmaa I, Danielsson A, Freyschuss U, Bergstrom J. A critical evaluation of ultrasound measurement of inferior vena cava diameter in assessing dry weight in normotensive and hypertensive hemodialysis patients. Am J Kidney Dis. 1997;30:459-465.
33. Greger R, Windhorst U. Comprehensive human physiology. From cellular mechanisms to integration. Berlin-Heidelberg: Springer Verlag; 1996.
34. Dieplinger H, Lackner C, Kronenberg F, Sandholzer C, Lhotta K, Hoppichler F, Graf H, König P. Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). J Clin Invest. 1993;91:397-401.
35. Demant T, Packard CJ, Demmelmair H, Stewart P, Bedynek A, Bedford D, Seidel D, Shepherd J. Sensitive methods to study human apolipoprotein B metabolism using stable isotope-labeled amino acids. Am J Physiol. 1996;270:E1022-E1036.
36. Packard CJ, Demant T, Stewart JP, Bedford D, Caslake MJ, Schwertfeger G, Bedynek A, Shepherd J, Seidel D. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. J Lipid Res. 2000;41:305-318.
37. Schultze G, Piefke S, Molzahn M. Blood pressure in terminal renal failure. Fluid spaces and the renin-angiotensin-system. Nephron. 1980;25:15-24.
38. Andrulli S, Colzani S, Mascia F, Lucchi L, Stipo L, Bigi MC, Crepaldi M, Redaelli B, Albertazzi A, Locatelli F. The role of blood volume reduction in the genesis of intradialytic hypotension. Am J Kidney Dis. 2002;40:1244-1254.
39. Menon V, Greene T, Wang X, Pereira AA, Marcovina SM, Beck GJ, Kusek JW, Collins AJ, Levey AS, Sarnak MJ. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int. 2005;68:766-772.
40. Pietzsch J, Lattke P, Julius U. Oxidation of apolipoprotein B-100 in circulating LDL is related to LDL residence time. In vivo insights from stable-isotope studies. Arterioscler Thromb Vasc Biol. 2000;20:E63-E67.
41. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green MS. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet. 2000;356:1213-1218.
42. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation. 2003;107:992-995.
43. Shoji T, Nishizawa Y, Kawagishi T, Kawasaki K, Taniwaki H, Tabata T, Inoue T, Morii H. Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. J Am Soc Nephrol. 1998;9:1277-1284.
44. Ericsson S, Eriksson M, Vitols S, Einarsson K, Berglund L, Angelin B. Influence of age on the metabolism of plasma low density lipoproteins in healthy males. J Clin Invest. 1991;87:591-596.
45. Millar JS, Lichtenstein AH, Cuchel M, Dolnikowski GG, Hachey DL, Cohn JS, Schaefer EJ. Impact of age on the metabolism of VLDL, IDL, and LDL apolipoprotein B-100 in men. J Lipid Res. 1995;36:1155-1167.
46. Quaschning T, Koniger M, Kramer-Guth A, Greiber S, Pavenstadt H, Nauck M, Schollmeyer P, Wanner C. Receptor-mediated lipoprotein uptake by human glomerular cells: comparison with skin fibroblasts and HepG2 cells. Nephrol Dial Transplant. 1997;12:2528-2536.
47. Pegoraro AA, Gudehithlu KP, Cabrera E, Shankar R, Arruda JA, Dunea G, Singh AK. Handling of low-density lipoprotein by the renal tubule: release of fragments due to incomplete degradation. J Lab Clin Med. 2002;139:372-378.
48. Oi K, Hirano T, Sakai S, Kawaguchi Y, Hosoya T. Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients. Kidney Int Suppl. 1999;71:S227-S228.
49. Grundy SM, Vega GL, Kesaniemi YA. Abnormalities in metabolism of low density lipoproteins associated with coronary heart disease. Acta Med Scand Suppl. 1985;701:23-37.
50. de Sain-van der Velden MG, Kaysen GA, Barrett HA, Stellaard F, Gadellaa MM, Voorbij HA, Reijngoud DJ, Rabelink TJ. Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis. Kidney Int. 1998;53:994-1001.
51. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001;59:260-269.
52. Nishizawa Y, Shoji T, Tabata T, Inoue T, Morii H. Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients. Kidney Int Suppl. 1999;71:S134-S136.
53. Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, Stehman-Breen CO. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 2002;61:297-304.
54. Vega GL, Grundy SM. Influence of lovastatin therapy on metabolism of low density lipoproteins in mixed hyperlipidaemia. J Intern Med. 1991;230:341-350.